Reason: Shutdown after failing to find a buyer
Last recorded trade on: February 24, 2023
Source: https://www.fiercebiotech.com/biotech/genocea-closes-shop-after-failing-find-buyer-delists-nasdaq
P/E ratio for Genocea Biosciences (GNCA)
P/E ratio on February 24, 2023 (TTM): -0.0002
According to Genocea Biosciences 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.000192308. At the end of 2021 the company had a P/E ratio of -2.42.
P/E ratio history for Genocea Biosciences from 2014 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | -2.42 | 15.84% |
| 2020 | -2.09 | 125.75% |
| 2019 | -0.9241 | |
| 2017 | -0.5859 | -75.12% |
| 2016 | -2.35 | -19.14% |
| 2015 | -2.91 | -1.84% |
| 2014 | -2.97 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Agenus
AGEN | -0.0676 | 35,044.77% | 🇺🇸 USA |
 Novavax NVAX | 2.31 | -1,199,176.48% | 🇺🇸 USA |
 Merck MRK | 12.0 | -6,229,690.03% | 🇺🇸 USA |
 iBio IBIO | -0.3026 | 157,245.51% | 🇺🇸 USA |
 Pfizer PFE | 17.5 | -9,090,725.45% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.